Metabolic Influences on Skeletal Fragility: Beyond Bone Density in Fracture Risk and Recovery
DOI:
https://doi.org/10.64784/237Palabras clave:
Bone fragility, Osteoporosis, Fracture risk, Metabolic disorders, Diabetes mellitus, Chronic kidney disease, Vitamin D deficiency, Osteosarcopenia, Bone health, Fracture healing, Musculoskeletal aging, Nutrition, Metabolic bone disease, Skeletal fragility, Recovery outcomesResumen
Bone fragility has traditionally been associated with osteoporosis and reduced bone mineral density; however, contemporary evidence indicates that fracture risk is influenced by a broader spectrum of metabolic, nutritional, endocrine, inflammatory, and musculoskeletal factors. The objective of this review was to analyze the metabolic determinants associated with bone fragility beyond osteoporosis and to examine their influence on fracture risk and recovery outcomes. A structured narrative review of scientific literature published in major biomedical databases was conducted, focusing on diabetes mellitus, chronic kidney disease, vitamin D deficiency, malnutrition, osteosarcopenia, endocrine dysfunction, and chronic inflammation. The findings demonstrated that these conditions contribute significantly to alterations in bone quality, remodeling capacity, muscle performance, and tissue repair, thereby increasing susceptibility to fragility fractures independently of bone mineral density measurements. Diabetes mellitus and chronic kidney disease emerged as major determinants of skeletal fragility due to their effects on collagen integrity, mineral metabolism, vascular function, and bone turnover. Nutritional deficiencies and inadequate vitamin D status were consistently associated with impaired mineralization, increased fall risk, and delayed fracture healing. Furthermore, osteosarcopenia highlighted the close biological relationship between bone and muscle health and its contribution to fracture susceptibility and functional decline. The evidence supports a multidimensional understanding of skeletal fragility that incorporates metabolic health into fracture prevention and management strategies. Expanding fracture risk assessment beyond traditional osteoporosis models may improve early identification of vulnerable individuals and facilitate more comprehensive approaches to prevention, treatment, and rehabilitation.
Referencias
• Albergaria, B. H., Chalem, M., Clark, P., Messina, O. D., Pereira, R. M. R., & Vidal, L. F. (2018). Consensus statement: Osteoporosis prevention and treatment in Latin America—Current structure and future directions. Archives of Osteoporosis, 13, 90.
• Aziziyeh, R., Amin, M., Habib, M., Garcia Perlaza, J., Szafranski, K., McTavish, R. K., Disher, T., Lüdke, A., Cameron, C., & Goeree, R. (2019). The burden of osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina. Journal of Medical Economics, 22(7), 638–644.
• Clark, P., Cons-Molina, F., Deleze, M., Ragi, S., Haddock, L., Zanchetta, J. R., Jaller, J. J., Palermo, L., Talavera, J. O., Messina, D. O., Morales-Torres, J., Salmerón, J., Navarrete, A., Suárez, E., Pérez, C. M., & Cummings, S. R. (2009). The prevalence of radiographic vertebral fractures in Latin American countries: The Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporosis International, 20(2), 275–282. https://doi.org/10.1007/s00198-008-0657-4
• Clynes, M. A., Gregson, C. L., Bruyère, O., Cooper, C., & Dennison, E. M. (2021). Osteosarcopenia: Where osteoporosis and sarcopenia collide. Rheumatology, 60(2), 529–537.
• Demay, M. B., et al. (2024). Vitamin D for the prevention of disease: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 109(8), 1907–1947.
• Haarhaus, M., Evenepoel, P., & European Renal Osteodystrophy Working Group. (2022). Management of fracture risk in CKD—Traditional and novel approaches. Clinical Kidney Journal, 15(3), 456–468.
• Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., Gordon, C. M., Hanley, D. A., Heaney, R. P., Murad, M. H., & Weaver, C. M. (2011). Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 96(7), 1911–1930.
• Hsu, C. Y., Chen, L. R., & Chen, K. H. (2020). Osteoporosis in patients with chronic kidney diseases: A systemic review. International Journal of Molecular Sciences, 21(18), 6846. https://doi.org/10.3390/ijms21186846
• Inoue, T., Maeda, K., Nagano, A., Shimizu, A., Ueshima, J., Murotani, K., Sato, K., & Tsubaki, A. (2021). Related factors and clinical outcomes of osteosarcopenia: A narrative review. Nutrients, 13(2), 291.
• Kanis, J. A., Johnell, O., Oden, A., Johansson, H., & McCloskey, E. (2008). FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporosis International, 19(4), 385–397. https://doi.org/10.1007/s00198-007-0543-5
• Karpouzos, A., Diamantis, E., Farmaki, P., Savvanis, S., & Troupis, T. (2017). Nutritional aspects of bone health and fracture healing. Journal of Osteoporosis, 2017, 4218472. https://doi.org/10.1155/2017/4218472
• Marsell, R., & Einhorn, T. A. (2011). The biology of fracture healing. Injury, 42(6), 551–555.
• Massé, O., et al. (2026). Calcium, vitamin D, or combined supplementation to prevent fractures and falls in older adults: Systematic review and meta-analysis. BMJ, 393, e088050.
• Moayeri, A., Mohamadpour, M., Mousavi, S. F., Shirzadpour, E., Mohamadpour, S., & Amraei, M. (2017). Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: A systematic review and meta-analysis. Therapeutics and Clinical Risk Management, 13, 455–468.
• Riera-Espinoza, G. (2009). Epidemiology of osteoporosis in Latin America 2008. Salud Pública de México, 51(Suppl. 1), S52–S55.
• Rojas, L. G. P., et al. (2022). Fragility fracture systems, Latin America perspective. Archives of Osteoporosis, 17, 105. https://doi.org/10.1007/s11657-022-01147-8
• Schini, M., Vilaca, T., Gossiel, F., Salam, S., Eastell, R., & Walsh, J. S. (2024). An overview of the use of the fracture risk assessment tool in osteoporosis. Osteoporosis International, 35, 501–512.
• Sellmeyer, D. E., Civitelli, R., Hofbauer, L. C., Khosla, S., Lecka-Czernik, B., & Schwartz, A. V. (2016). Skeletal metabolism, fracture risk, and fracture outcomes in type 1 and type 2 diabetes. Diabetes, 65(7), 1757–1766.
• van Oostwaard, M. (2018). Osteoporosis and the nature of fragility fracture: An overview. In Fragility Fracture Nursing (pp. 1–13). Springer.
• Wang, H., Ba, Y., Xing, Q., & Du, J. L. (2019). Diabetes mellitus and the risk of fractures at specific sites: A meta-analysis. BMJ Open, 9(1), e024067.
